

RECEIVED
CENTRAL FAX CENTER

MAR 23 2006

FACSIMILE TRANSMISSION

TO: United States Patent & Trademark Office

PAGES: 1 of 4

FROM: David W. Osborne

FACSIMILE NO.: 1-571-273-8300

DATE: March 23, 2006

TRANSMITTED BY: Julia Seargeant

OUR DOCKET NO.: T7770.CON5/ Patent Application No. 10/731,039

SUBJECT: INTERVIEW SUMMARY

Commissioner For Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir/Madam:

Transmitted herewith is an INTERVIEW SUMMARY for Attorney Docket No. T7770.CON5, Application No. 10/731,039. Thank you.

Sincerely,

David W. Osborne
Thorpe North & Western, LLP
Customer No. 28,122
Reg. No. 44,989

The pages that follow may contain sensitive, privileged or confidential information intended solely for the addressee named above. If you receive this message and are not the agent or employee of the addressee, and have therefore been sent or received this communication in error, you are asked not to disseminate or copy any of the attached and are to notify the sender immediately by telephone. Please also return the original message to the sender by mail. Thank you.

www.tnw.com

8180 South 700 East • Suite 200 • Sandy, Utah 84070-0552 • 801.566.6633 • 1.801.566.0750 • pdlaw@tnw.com U.S. Mailing Address: P.O. Box 1219 • Sandy, Utah 84091-1219

The Team Approach to Premier Performance®

RECEIVED
CENTRAL FAX CENTERPATENT APPLICATION
DOCKET NO. T7770.CON5MAR 23 2006
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Steven W. Sanders	CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. § 1.8
SERIAL NO.: 10/731,039	I hereby certify under 37 CFR § 1.8 that this correspondence is being facsimile transmitted to the USPTO or being deposited with the United States Postal Service with sufficient postage as first class postage in an envelope addressed to Mail Stop Non-Fee Amendment/Response Commissioner of Patents P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.
FILED: 12/08/2003	
COMPOSITIONS AND METHODS FOR MINIMIZING ADVERSE DRUG EXPERIENCES ASSOCIATED WITH OXYBUTYNIN THERAPY	
ART UNIT: 1615	
EXAMINER: Ghali, Isis A D	Name <u><i>Isis A D Ghali</i></u>
DOCKET NO.: T7770.CON5	<u>3/23/2006</u> Date of Deposit

INTERVIEW SUMMARY

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In view of the Examiner interview held on February 14, 2006, please enter this Statement of the Substance of the Interview pursuant to 37 C.F.R. § 1.133.

Page 1 of 3

INTERVIEW SUMMARY

A telephonic interview was held on February 14, 2006 between Applicant's representative, Mr. David Osborne and Examiner Isis Ghali. During the interview, the Examiner informed applicant's representative that claim 1 was rejected under statutory double patenting in view of the combination of claims 1 and 12 of issued United States Patent No. 6,743,441, and further that claim 21 was also rejected under statutory double patenting in view of the combination of claims 15 and 26 in the same issued United States Patent. It was agreed that amending claim 1 to include the subject matter of claim 4 and amending claim 21 to include the subject matter of claim 24 rendered such double patenting rejection moot. Applicant's representative authorized the Examiner to make the foregoing amendments and to further cancel claims 4 and 24 via an Examiner's Amendment. Further, applicant's representative authorized the Examiner to amend the dependency of claims 5 and 25 to be proper in view of the foregoing amendment.

CONCLUSION


If any impediment to the entry of this Interview Summary is discovered, and such impediment could be removed during a further telephone interview, the Examiner is invited to telephone either the undersigned attorney at (801) 566-6633, so that such issues may be resolved as expeditiously as possible.

Please charge any additional fees except for Issue Fee or credit any overpayment to Deposit Account No. 20-0100.

Dated this 21st day of March, 2006.

Respectfully submitted,

THORPE, NORTH & WESTERN, LLP



David W. Osborne
Reg. No. 44,989
8180 South 700 East, Suite 200
Sandy, UT 84070
Telephone: (801) 566-6633
Facsimile: (801) 566-0750